| US 7,473,431 B2 | ||
| Injectable methadone, methadone and naltrexone, or buprenorphine and naltrexone microparticle compositions and their use in reducing consumption of abused substances | ||
| Thomas R. Tice, Birmingham, Ala. (US); Jay K. Staas, Alabaster, Ala. (US); Teresa M. Ferrell, Vestavia Hills, Ala. (US); and Peter Markland, Birmingham, Ala. (US) | ||
| Assigned to Brookwood Pharmaceuticals, Inc., Birmingham, Ala. (US) | ||
| Filed on Dec. 17, 2002, as Appl. No. 10/324,062. | ||
| Application 10/324062 is a continuation of application No. 09/648255, filed on Aug. 25, 2000, granted, now 6,495,155. | ||
| Claims priority of provisional application 60/151112, filed on Aug. 27, 1999. | ||
| Prior Publication US 2003/0152638 A1, Aug. 14, 2003 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61F 2/00 (2006.01) | ||
| U.S. Cl. 424—426 [424/425; 424/424; 424/497] | 12 Claims |
| 1. A slow release formulation comprising:
a mixture of a first population of microspheres and a second population of microspheres, wherein said first population comprises
a buprenorphine and a residual amount of ethyl acetate that is from about 0.1 to about 3 weight %, and said second population
comprises an naltrexone and a residual amount of ethyl acetate that is less than about 3 weight % ethyl acetate, and wherein
said mixture provides a therapeutically effective dose of medication for the treatment of at least one of heroin and alcohol
abuse for a period of at least 28 days when said slow release formulation is introduced into a mammal.
|